OptimizeRx Corp. (OPRX) earned a Buy rating upgrade following an improved 2027 growth outlook. Analysts identified the company's attractive valuation as a primary catalyst for the move.
A strategic shift toward higher-margin products delivered five consecutive quarters of gross margin expansion. Gross margins reached 76.5% in the second quarter of 2026. While second-quarter revenue declined year-over-year, the results exceeded analyst expectations.
Management reaffirmed full-year 2026 revenue guidance between $95 million and $100 million. Adjusted EBITDA for the same period is expected to range from $21 million to $25 million.
The stock currently trades at a significant discount to the sector median forward P/E ratio. Technical analysis indicates potential for further gains as the company executes its growth strategy.